If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Interim Results

16 Oct 2008 07:00

RNS Number : 9607F
Oxeco PLC
16 October 2008
Ā 



16 October 2008

Oxeco Plc (the "Company"Ā or theĀ "Group" )

Interim financial report for the six months ended 31 July 2008

Chairman's Statement

I am pleased toĀ report on yourĀ Group'sĀ performanceĀ for the six months ended 31 July 2008.Ā 

OxecoĀ PlcĀ is a holding and management company, specialising in the development and growth of tradingĀ businessesĀ within theĀ technology and science sectors. The Company currently hasĀ one subsidiary, Oxray Ltd, which was acquired in June 2007 and is aĀ start up business which aims to become a leading provider of molecular structure determination services to both industry and academic institutions.Ā 

The unaudited consolidated loss before tax for the Group in six months to 31 July 2008 amounted to £105,000 compared to £3,000 for the comparable period from incorporation on 17 October 2006 to 31 July 2007. Consolidated net assets at 31 July 2008 amounted to £4.77 million including cash balances of £2.64 million versus net assets of £4.93 million and cash balances of £2.81 million a year earlier at 31 July 2007. The cash outflow for the Group during the six months to 31 July 2008 amounted to £120,000 and cash balances continue to be managed prudently, with tight cost control.

Oxray's primary objectives are the development of novel X-ray crystallography structure determination software and the provision of a small-molecule X-ray crystallography structure service. The service usesĀ a web portal behind which the company canĀ work toĀ maximiseĀ the extent to which the service can be automated. TheĀ CompanyĀ offersĀ standardisedĀ response times to its customers but alsoĀ offersĀ market premium services such as a fast-response and extended scientific reporting suitable to support customers' patent applications.Ā Oxray expects to complete the initial development of it's X-ray crystallography structure determinationĀ softwareĀ within the next six monthsĀ and will then focus on the marketing of the service and the establishment of a solid customer base.

OxecoĀ PlcĀ is well capitalised andĀ I am confident that your Company will continue toĀ make considerable progress in its development duringĀ the second half of the yearĀ despite turbulent financial markets.Ā Your DirectorsĀ are continuing to evaluate a range of new commercial and acquisition opportunities which they believe fulfil the Company's original objectives of investing in the technology and science sectors, and especially those which are complimentary to the existing Group activities.

Finally I would like to conclude by thanking our employees and management for their hard work and support in the growth and development of theĀ GroupĀ in the period.

Jussi Westergren

Executive Chairman

Contact:

Michael Bretherton

Oxeco plc

www.oxecoplc.com

+44 (0) 207352 8989

Ā Ray Zimmerman/Jonathan Evans

Zimmerman Adams International Limited

+44 (0) 207 060 1760

Daniel Briggs

Religare Hichens, Harrison plc

+44 (0) 207 382 7776

Ā 

Ā 

Ā 

Ā 

OXECO PLC

CONDENSED CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTHS TO 31 JULY 2008

Ā 
Notes
Six months to 31 July
2008
(Unaudited)
Period to
31 July
2007
(Unaudited)
Period to
31 January
2008
(Audited)
Ā 
Ā 
Ā£000
Ā£000
Ā£000
Ā 
Ā 
Ā 
Ā 
Ā 
Revenue
Ā 
6
-
7
Administrative expenses
Ā 
(188)
(95)
(243)
Ā 
Ā 
Ā 
Ā 
Ā 
Operating Loss
Ā 
(182)
(95)
(236)
Ā 
Ā 
Ā 
Ā 
Ā 
Interest receivable
Ā 
77
92
178
Ā 
Ā 
Ā 
Ā 
Ā 
Loss before tax
Ā 
(105)
(3)
(58)
Ā 
Ā 
Ā 
Ā 
Ā 
Taxation
2
3
–
(5)
Ā 
Ā 
Ā 
Ā 
Ā 
Loss for the period
Ā 
(102)
(3)
(63)
Earnings per share Basic and Diluted
3
(0.02p)
(0.00)p
(0.01)p
Ā 
Ā 

Ā 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

The loss for the period arises from the Group's continuing operations.

CONDENSED CONSOLIDATEDĀ STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS TO 31 JULY 2008

Ā 
Share Capital £000
Share Premium £000
Retained Loss £000
Total Equity £000
At 17 October 2006
–
–
–
–
Issue of shares
600
4,500
–
5,100
Expenses of issue of shares
–
(167)
–
(167)
Loss for the period
–
–
(3)
(3)
At 31 July 2007
600
4,333
(3)
4,930
Loss for the period
-
-
(60)
(60)
At 31 January 2008
600
4,333
(63)
4,870
Loss for the period
-
-
(102)
(102)
At 31 July 2008
600
4,333
(165)
4,768
Ā 
Ā 

OXECO PLC

CONDENSED CONSOLIDATED BALANCE SHEET

AS AT 31 JULY 2008

Ā 
Notes
31 July 2008
31 July 2007
31 January 2008
Ā 
Ā 
(Unaudited)
(Unaudited)
(Audited)
Ā 
Ā 
Ā£000
Ā£000
Ā£000
ASSETS
Non-current assets
Ā 
Ā 
Ā 
Ā 
Property, plant and equipment
Ā 
1
1
2
Intangible assets - goodwill
Ā 
2,120
2,120
2,120
Total non-current assets
Ā 
2,121
2,121
2,122
Ā 
Ā 
Ā 
Ā 
Ā 
Current assets
Ā 
Ā 
Ā 
Ā 
Trade and other receivables
Ā 
38
16
29
Cash and cash equivalents
Ā 
2,641
2,816
2,761
Total current assets
Ā 
2,679
2,832
2,790
Ā 
Ā 
Ā 
Ā 
Ā 
TOTAL ASSETS
Ā 
4,800
4,953
4,912
Ā 
Ā 
Ā 
Ā 
Ā 
LIABILITIES
Ā 
Ā 
Ā 
Ā 
Current Liabilities
Ā 
Ā 
Ā 
Ā 
Trade and other payables
Ā 
(30)
(23)
(37)
Current taxation
Ā 
(2)
-
(5)
Ā 
Ā 
Ā 
Ā 
Ā 
TOTAL LIABILITIES
Ā 
(32)
(23)
(42)
Ā 
Ā 
Ā 
Ā 
Ā 
NET ASSETS
Ā 
4,768
4,930
4,870
Ā 
Ā 
Ā 
Ā 
Ā 
EQUITY
Ā 
Ā 
Ā 
Ā 
Issued capital
3
600
600
600
Share premium
Ā 
4,333
4,333
4,333
Revenue reserve
Ā 
(165)
(3)
(63)
TOTAL EQUITY SHAREHOLDERS’ FUNDS
Ā 
4,768
4,930
4,870
Ā 
Ā 

Ā 

Approved by the Board andĀ authorisedĀ for issueĀ onĀ 16Ā October 2008.

J P Westergren MĀ A Bretherton

Chairman Finance Director

OXECO PLC

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

FOR THE SIX MONTHS ENDEDĀ 31 JULY 2008

Ā 
Six months to
31 July 2008
Period to
31 July 2007
Period to
31 January 2008
Ā 
(Unaudited)
(Unaudited)
(Audited)
Ā 
Ā£000
Ā£000
Ā£000
OPERATING ACTIVITIES
Ā 
Ā 
Ā 
Operating loss before taxation
(182)
(95)
(236)
Depreciation of property, plant and equipment
1
-
-
Increase in trade and other receivables
(9)
(16)
(29)
Decrease in trade and other payables
(7)
(30)
(15)
Net cash outflow from operations
(197)
(141)
(280)
Ā 
Ā 
Ā 
Ā 
INVESTING ACTIVITIES
Ā 
Ā 
Ā 
Purchase of property, plant and equipment
-
-
(2)
Acquisition of subsidiaries
-
(100)
(100)
Cash and bank in subsidiaries at acquisition
-
32
32
Net cash outflow from investing activities
-
(68)
(70)
Ā 
Ā 
Ā 
Ā 
FINANCING ACTIVITIES
Ā 
Ā 
Ā 
Proceeds from issue of share capital
-
3,100
3,100
Expenses of issue of share capital
-
(167)
(167)
Interest received
77
92
178
Net cash inflow from financing activities
77
3,025
3,111
Ā 
Ā 
Ā 
Ā 
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS
(120)
2,816
2,761
Ā 
Ā 
Ā 
Ā 
Cash and cash equivalents at start of period
2,761
–
-
Ā 
Ā 
Ā 
Ā 
CASH AND CASH EQUIVALENTS AT END OF PERIOD
2,641
2,816
2,761
Ā 
Ā 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

OXECO PLC

NOTES TO THE CONDENSED FINANCIAL STATEMENTSĀ 

FOR THE SIX MONTHS ENDEDĀ 31 JULY 2008

1) SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

The interim financial statements of Oxeco Plc are unaudited condensed consolidated financial statements for the period for the six months period to 31 July 2008. These includeĀ unaudited comparatives for theĀ period from incorporation onĀ 17Ā OctoberĀ 2006Ā to 31 July 2007 together with audited comparatives for the period fromĀ incorporation on 17 October 2006 to 31 July 2007.

The condensed consolidated financial statements have been prepared under the historic cost convention and incorporate the financials of Oxeco Plc for the period and its subsidiary undertaking from the date of acquisition.

The accounting policies adopted are consistent with those followed in the preparation of the Group's annual financial statements for the period ended 31 January 2008.

The condensed consolidated financial statements do not constitute statutory accounts. The statutory accounts for the period to 31 January 2008 have been reported on by the Company's auditors and have been filed with the Registrar of Companies. The report of the auditors was unqualifiedĀ and did not contain a statement under section 237(2) or 237(3) of the Companies Act 1985.

2) TAXATION

The accrued tax charge for the six month period is based on an estimated effective tax rate of nil, after allowance for utilisation of tax losses brought forward in subsidiaries and prior year adjustments, (period to 31 July 2007: effective tax rate nil, period to 31 January 2008: effective tax rate 8.6 per cent.).

3) LOSS PER SHARE

Basic loss per share is based on the net loss for the period of £102,000 attributable to equity holders of the parent divided by the weighted average number of ordinary shares in issue during the period of 600,000,000, (period to 31 July 2007: loss £3,000 divided by the weighted average number of 353,658,537 shares; period to 31 January 2008: loss £63,000 divided by the weighted average of 456,050,955 shares). Fully diluted earnings per share are the same as basic earnings per share.

4) SHARE CAPITAL
Number
£’000
Authorised ordinary shares of 1p:
Ā 
Ā 
Ā 
Ā 
Ā 
AtĀ 31 July 2007,Ā 31 January 2008 and 31 July 2008
1,000,000,000
1,000
Ā 
Ā 
Ā 
Allotted, issued and fully paid ordinary shares of 1p:
Ā 
Ā 
Ā 
Ā 
Ā 
AtĀ 31 July 2007,Ā 31 January 2008 and 31 July 2008
600,000,000
600
Ā 
Ā 

5) RELATED PARTY TRANSACTIONS

During the periodĀ the CompanyĀ entered into the following transactions with Ora Capital Partners PlcĀ (ORA)Ā which as at 31 July 2008Ā heldĀ 45.25% of theĀ Company'sĀ issued share capital.

Ā 
Six months to
31 July
Ā 2008
Period to
31 July
2007
Period to
31 January 2008
Ā 
(Unaudited)
(Unaudited)
(Audited)
Ā 
Ā£000
Ā£000
Ā£000
Management consultancy fees charged by ORA
6
7
18
Ā 

Ā 

During the period the Company's wholly owned subsidiary, Oxray Ltd, borrowed £nil (31 July 2007: £100,000)  from the Company for working capital purposes. The loan is non-interest bearing, is repayable on demand and the outstanding balance at 31 July 2008 was £200,000 (31 July 2007: £100,000).

6)Ā INTERIM FINANCIAL REPORT

A copy of this interim report will be distributed to shareholders and is also available on the Company's website at www.oxecoplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
IR ILFLDISLELIT
Date   Source Headline
27th Jul 20209:59 amRNSHoldings in Company
24th Jul 20207:00 amRNSCommencement of facility expansion plan
23rd Jul 20206:22 pmRNSHoldings in Company
17th Jul 20209:56 amRNSHoldings in Company
10th Jul 20203:18 pmRNSHoldings in Company
6th Jul 20209:31 amRNSHoldings in Company
3rd Jul 202010:01 amRNSHoldings in Company
30th Jun 20204:44 pmRNSTotal Voting Rights
30th Jun 202010:42 amRNSResult of AGM
23rd Jun 20203:07 pmRNSOption Exercise and Total Voting Rights
17th Jun 202012:57 pmRNSHoldings in Company
15th Jun 20202:06 pmRNSSecond Price Monitoring Extn
15th Jun 20202:00 pmRNSPrice Monitoring Extension
15th Jun 202011:31 amRNSHoldings in Company
11th Jun 20204:54 pmRNSHoldings in Company
11th Jun 20204:26 pmRNSHoldings in Company
11th Jun 20201:21 pmRNSHoldings in Company
11th Jun 202011:20 amRNSHoldings in Company
11th Jun 202011:05 amRNSSecond Price Monitoring Extn
11th Jun 202011:00 amRNSPrice Monitoring Extension
10th Jun 20204:53 pmRNSHoldings in Company
10th Jun 20204:51 pmRNSHoldings in Company
10th Jun 20204:49 pmRNSHoldings in Company
10th Jun 20204:35 pmRNSHoldings in Company
9th Jun 20201:10 pmRNSResult of General Meeting and Total Voting Rights
5th Jun 20209:15 amRNSDirector subscriptions/PDMR dealing
5th Jun 20207:00 amRNSAnnual results for the year ended 31 December 2019
4th Jun 20204:41 pmRNSSecond Price Monitoring Extn
4th Jun 20204:35 pmRNSPrice Monitoring Extension
3rd Jun 20202:05 pmRNSSecond Price Monitoring Extn
3rd Jun 20202:00 pmRNSPrice Monitoring Extension
1st Jun 20209:05 amRNSSecond Price Monitoring Extn
1st Jun 20209:00 amRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSCE Mark awarded for OrthoPure XT
29th May 202011:05 amRNSSecond Price Monitoring Extn
29th May 202011:00 amRNSPrice Monitoring Extension
27th May 20204:41 pmRNSSecond Price Monitoring Extn
27th May 20204:36 pmRNSPrice Monitoring Extension
26th May 20207:00 amRNSPublication of circular and notice of GM
22nd May 20202:00 pmRNSPrice Monitoring Extension
22nd May 202011:05 amRNSSecond Price Monitoring Extn
22nd May 202011:00 amRNSPrice Monitoring Extension
22nd May 20207:00 amRNSConfirmation of successful fundraising
21st May 20204:47 pmRNSPrimaryBid.com Offer
21st May 20204:43 pmRNSProposed Equity Fundraise
11th May 20207:00 amRNSNew collaboration with leading healthcare company
20th Apr 20207:00 amRNSAdditional US government-backed loan secured
15th Apr 20207:00 amRNSUS Government backed loan extends cash runway
3rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
3rd Apr 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.